Group 1 - The company has reached agreements with KGBio and Abbott regarding exclusive commercialization rights for the product Hansuz® (Sruilumab injection) in specified regions [1][2] - The original KGBio licensing agreement has been partially terminated, specifically for regions outside of Indonesia, allowing for a shift in commercialization rights [1] - The revised agreement with Abbott expands the licensing area and milestone payment terms, enhancing the product's market reach in Latin America and the Caribbean [1][2] Group 2 - The termination of the KGBio agreement allows the company to grant exclusive commercialization rights to Abbott in newly added regions, which includes the previously terminated areas [2] - The collaboration with Abbott is expected to strengthen the company's international market presence and product accessibility [2]
复宏汉霖(02696.HK)：修订就汉斯状®与ABBOTT及KGBIO的许可协议